Biomarkers for Palbociclib in Fulvestrant-Resistant Metastatic Breast Cancer Using cfDNA Cancer Panel Sequencing

被引：0
|
作者：
Takeshita, Takashi [1 ]
Iwamoto, Takayuki [2 ]
Niikura, Naoki [3 ]
Watanabe, Kenichi [4 ]
Kikawa, Yuichiro [5 ]
Kobayashi, Kokoro [6 ]
Okamura, Takuho [3 ]
Tada, Hiroshi [7 ]
Ozaki, Shinji [8 ]
Toh, Uhi [9 ]
Yamamoto, Yutaka [1 ]
Tsuneizumi, Michiko [10 ]
Ishiguro, Hiroshi [11 ]
Masuda, Norikazu [12 ]
Saji, Shigehira [13 ]
机构：
[1] Kumamoto City Hosp, Dept Breast & Endcrine Surg, Kumamoto, Japan
[2] Kawasaki Med Sch Hosp, Dept Breast & Thyroid Surg, Kawasaki, Japan
[3] Tokai Univ, Sch Med, Dept Breast Oncol, Tokai, Japan
[4] NHO Hokkaido Canc Ctr, Det Breast Oncol, Sapporo, Japan
[5] Kansai Med Univ Hosp, Dept Breast Surg, Hirakata, Japan
[6] Saitama Red Cross Hosp, Dept Med Oncol, Saitama, Japan
[7] Tohoku Univ Hosp, Dept Breast & Endocrine Surg, Sendai, Japan
[8] Hiroshima Prefectural Hosp, Dept Gastrointestinal & Breast Surg, Hiroshima, Japan
[9] Kurume Univ, Hosp Dept Breast Surg, Kurume, Japan
[10] Shizuoka Prefectural Gen Hosp, Dept Breast Surg, Shizuoka, Japan
[11] Saitama Med Univ, Int Med Ctr, Breast Oncol Serv, Saitama, Japan
[12] Kyoto Univ, Grad Sch, Dept Breast Surg, Med Div, Kyoto, Japan
[13] Fukushima Med Univ, Sch Med, Dept Med Oncol, Fukushima, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E-3050
引用
收藏
页码：1890 / 1890
页数：1
相关论文
共 50 条
  • [1] Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing
    Takeshita, T.
    Iwamoto, T.
    Niikura, N.
    Watanabe, K.
    Kikawa, Y.
    Kobayashi, K.
    Iwakuma, N.
    Okamura, T.
    Tada, H.
    Ozaki, S.
    Okuno, T.
    Toh, U.
    Yamamoto, Y.
    Tsuneizumi, M.
    Ishiguro, H.
    Masuda, N.
    Saji, S.
    ESMO OPEN, 2024, 9 (04)
  • [2] High-Dose Toremifene for Fulvestrant-Resistant Metastatic Breast Cancer: A Report of Two Cases
    Mori, Ryutaro
    Nagao, Yasuko
    CASE REPORTS IN ONCOLOGY, 2014, 7 (02): : 383 - 388
  • [3] Palbociclib and Fulvestrant in Breast Cancer
    McCaw, Zachary R.
    Vassy, Jason L.
    Wei, Lee-Jen
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08): : 796 - 796
  • [4] Palbociclib and Fulvestrant in Breast Cancer Reply
    Turner, Nicholas C.
    Huang, Xin
    Cristofanilli, Massimo
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08): : 797 - 797
  • [5] Palbociclib plus fulvestrant in a positive hormonal receptors metastatic breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 1032 - 1033
  • [6] Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer
    Tsuboi, Kouki
    Kaneko, Yosuke
    Nagatomo, Takamasa
    Fujii, Rika
    Hanamura, Toru
    Gohno, Tatsuyuki
    Yamaguchi, Yuri
    Niwa, Toshifumi
    Hayashi, Shin-ichi
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2017, 167 : 115 - 125
  • [7] Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells
    Zhou, Qian
    Zeng, Hui
    Ye, Peng
    Shi, Yu
    Guo, Juan
    Long, Xinghua
    ANTI-CANCER DRUGS, 2018, 29 (06) : 539 - 548
  • [8] RBsig geneexpression signature in patients with endocrine resistant metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial
    Benelli, Matteo
    Tyekucheva, Svitlana
    Crestani, Thayane
    Ignatiadis, Michail
    Neven, Patrick
    Colleoni, Marco
    Henry, Stephanie
    Papadimitriou, Konstantinos
    Bernardo, Antonio
    Seles, Elena
    Duhoux, Francois
    Macpherson, Iain
    Thomson, Alastair
    Davies, David Mark
    Migliaccio, Ilenia
    Zoppoli, Gabriele
    Kammler, Roswitha
    De Swert, Heidi
    Ruepp, Barbara
    Aftimos, Philippe
    Seoane, Jose
    Romagnoli, Dario
    Venet, David
    Goulioti, Theodora
    Cameron, David
    Loi, Sherene
    Piccart, Martine
    Regan, Meredith
    Malorni, Luca
    CANCER RESEARCH, 2024, 84 (09)
  • [9] Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
    Colombo, Giorgio Lorenzo
    Valentino, Maria Chiara
    Fabi, Alessandra
    Dieci, Maria Vittoria
    Caruggi, Mauro
    Bruno, Giacomo Matteo
    Lombardi, Gloria
    Di Matteo, Sergio
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 301 - 312
  • [10] Exploration of targets and molecular mechanisms of cinnamaldehyde in overcoming fulvestrant-resistant breast cancer: a bioinformatics study
    Adam Hermawan
    Herwandhani Putri
    Rohmad Yudi Utomo
    Network Modeling Analysis in Health Informatics and Bioinformatics, 2021, 10
12345